Phio Pharmaceuticals Corporation (PHIO) 시세

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176074282

Lol

Color me crazy....again. 2.23 it's like it was talking to me with it's eyes. lol

See the % gains here, Spuds! We're pushing $3 :) The strength of the team is each individual member. The strength of each member is the team.😍♥️

I started to scan for something before leaving out and thought I'd just check my watchlist and this one was there. So lucky for that.
GLTU 81

PS: I had a 89 for a few years. Love that they already had a 6 spd at that time. That was something new for me back then.
I wasn't used to getting over 100mph and still have 2 gears left. 🤪

PHIO,nice grab! I should have bought it yesterday but I wanted 3 solder candles for confirmation of run continue not a pump and dump on no news,bought on the only dip in death hr,had many bids in(2.54 only filled)
Maybe news and a gap up to $10 tomorrow is going to be the hype,hope,fomo.
No shares showing up to short is promising,solid zb,it does hint big news coming if they won’t loan out their shares to short
Good skill to you bro!

Jumped into this one about 7:05 this morning @ 2.23 and had to run out.
Just added 2.87

PHIO going for nhod in death hr,moving freely on low vol,expect vol surges soon that increase,has gapped to $10 before so greed could be strong,also skin cancer cure for potential

bids filling,ZB/126%fee(no rebate)charting up,moving freely

Spending 150% of cash how much burn is going to be needed to finish phase 2 and phase 3 and get fda approvals and then distribution and a lot of other fees expenses and hopefully works if does hell yeah will be bought by another company imo but won't be for a long time and have to do more R&D. then the company technically will only have a paycheck.

"You bet your sweet bippy" 🥰

Nice move PHIO

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
Newsfile Corp.
Newsfile Corp
-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentration

Marlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in Phio's Phase 1b clinical trial (NCT 06014086) for Phio's lead product candidate, PH-762.

Phio's Phase 1b clinical trial is a multi-center, dose-escalating trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This trial assesses the tumor response and determines the recommended dose for further study of PH-762. In the third cohort of this trial, three patients with cutaneous squamous cell carcinoma were enrolled. For these patients, injections were well tolerated with no serious adverse events and there were no dose-limiting toxicities. Pathology results related to efficacy of PH-762 in the third cohort are forthcoming.

"We are impressed with the continuing safety profile of PH-762 having now progressed through the first 3 escalating doses," said Mary Spellman, MD, Phio's acting Chief Medical Officer.

Previously, seven patients diagnosed with cutaneous carcinomas were treated in dose cohorts 1 and 2. The second cohort enrolled a total of 4 patients who were diagnosed with cutaneous squamous cell carcinoma. At Day 36 (tumor excision) in the second cohort, two patients had a complete response (100% tumor clearance), and one patient had a partial response (90% clearance). All three patients in cohort 1 and one patient in cohort 2 maintained stable disease.

"We are optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer," said Robert Bitterman, President and CEO of Phio Pharmaceuticals.

About Phio Pharmaceuticals Corp.

lol made nothing today ahh lost 200

LMFAO!🤣 and I always thought it was the other way around!🤑😋

i make a grand a day 5 days and then jack off

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
Newsfile Corp.
Newsfile Corp
Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-762

3rd Cohort now fully enrolled in on-going clinical study

Marlborough, Massachusetts--(Newsfile Corp. - March 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today reported its financial results for the year ended December 31, 2024, and provided a business update.

Recent Corporate Updates

PH-762 Clinical Progress

PH-762 is currently being evaluated in a U.S. multi-center Phase 1b dose-escalating clinical trial through the intratumoral injection of PH-762 for the treatment of patients with cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. The trial (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762 in up to 30 patients to assess tumor response and determine the dose or dose range for continued study of PH-762 in future trials. In May and December 2024, respectively, a Safety Monitoring Committee (SMC) reviewed data from the first and second dose cohorts treated with PH-762, and in both instances recommended escalation to the next dose concentration. A total of 7 patients with cutaneous carcinomas have been enrolled in dose cohorts 1 and 2. The second cohort enrolled a total of 4 patients, all of whom were diagnosed with cutaneous squamous cell carcinoma. At Day 36 (tumor excision), a complete response (100% tumor clearance) was reported for 2 patients, a partial response (90% tumor clearance) was reported for 1 patient and 1 patient had stable disease, having not progressed. Patients in the first cohort maintained stable disease.

To date, intratumoral injection of PH-762 has been well tolerated in all enrolled patients. There were no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects in the patients receiving intratumoral PH-762. The third dose cohort is fully enrolled and patients in this cohort are currently in the treatment or follow-up phase of the study. Phio expects to complete enrollment of all patients in the study in the third quarter of 2025.

Capital Sourcing

In December 2024 and January 2025, Phio raised an aggregate of approximately $9.2 million in registered direct offerings and concurrent private placements, before deduction of commissions and other expenses. Additional gross proceeds of approximately $2.9 million were raised from the exercise of warrants previously issued on July 12, 2024. With these proceeds, the Company now believes it has sufficient capital to complete the treatment phase of the Phase 1b trial.

Cost Rationalization

In 2023, Phio commenced a cost rationalization program resulting from its strategy to transition from discovery research to a product development focus. In combination with headcount reductions, Phio did not renew its building lease in Marlborough, MA., the lease for which expired on March 31, 2024. The Company has established a smaller research footprint in the Massachusetts Biomedical Initiatives in Worcester, MA, where the Company leases laboratory space. Expense reductions have been redirected to funding the Phase 1b clinical trial for PH-762.

In May 2024, Phio terminated its Clinical Co-Development Agreement with AgonOx, Inc. (AgonOx). The Clinical Co-Development Agreement was entered into to conduct a Phase 1 clinical trial of PH-762 in combination with Agonox's "double positive" tumor infiltrating lymphocytes (DP TIL) in patients with advanced melanoma and other advanced solid tumors. The primary trial objectives were to evaluate the safety and to study the potential for enhanced therapeutic benefit from the administration of PH-762 treated DP TIL. AgonOx had enrolled three patients. The first two patients were treated with DP TIL only, and a third patient was treated with a combination of DP TIL and PH-762. Clinical results for the single patient who received a combination of DP TIL and PH-762. Clinical results for the single patient who received a combination of DP TIL and PH-762 showed tumor size reductions of 65%, 100% and 81%, respectively, in three melanoma lesions. In assessing patient enrollment delays and the cost to continue the trial, management chose to redirect funding and focus on its self-directed phase 1b clinical trial with PH-762.

Patent Portfolio Enhancement

Phio's portfolio includes 77 issued patents, 69 of which cover its INTASYL technology. There are 19 patent families broadly covering both the composition and methods of use of the Company's self-delivering INTASYL technology and uses of INTASYL compounds targeting immune checkpoints for cancer therapy, cellular differentiation and metabolism targets for Adoptive Cell Therapy immunotherapies.

Scientific News

During 2024, Phio presented new data on its INTASYL self-delivering siRNA technology applications at several conferences including American Academy of Cancer Research (AACR), Society for Immunotherapy of Cancer (SITC), American Society of Gene and Cell Therapy (ASGCT) and at the Annual Oligonucleotide Therapeutics Society (OTS). Most recently, the Company was invited to present its phase 1b clinical trial results to date at the American Academy of Dermatology (AAD) in the Late-Breaking Research Session. The Company's INTASYL PH-804 compound was highlighted in the peer reviewed journal, Cancer Immunology, Immunotherapy in an article entitled, "INTASYL Self Delivering RNAi Decreases TIGIT Expression, Enhancing NK Cell Cytotoxicity: A Potential Application to Increase the Efficacy of NK Adoptive Cell Therapy Against Cancer", authored by M. Maxwell et al.

Financial Results

Cash Position

At December 31, 2024, the Company had cash of approximately $5.4 million as compared with approximately $8.5 million at December 31, 2023.

During the year ended December 31, 2024, the Company completed multiple financings and received total net proceeds of approximately $4.0 million after deducting placement agent fees and offering expenses.

Subsequent to year-end, the Company completed additional financings and received total net proceeds of approximately $6.8 million after deducting placement agent fees and offering expenses.

Research and Development Expenses

Research and development expenses for the year ended December 31, 2024 decreased approximately $2.7 million, or 42%, as compared with the year ended December 31, 2023. The decrease in research and development expenses was primarily driven by the Company's cost rationalization measures in transitioning from a research company to a product development company. These actions resulted in a decrease of approximately $1.0 million of expense due to the wind-down of preclinical studies, a reduction of approximately $0.8 million in salary-related costs including stock-based compensation expense, and approximately $0.2 million in lab supplies associated with the reduction in headcount. Additionally, the Company experienced a reduction in clinical consulting fees and clinical trial-related fees of approximately $0.4 million incurred in connection with its IND filing for PH-762 and its former PH-762 trials in ACT and European clinical trial, as well as a decrease of approximately $0.2 million in manufacturing fees for PH-762 compared with 2023.

General and Administrative Expenses

General and administrative expenses were approximately $3.7 million for the year ended December 31, 2024 as compared with approximately $4.4 million for the year ended December 31, 2023, a decrease of 14%. The decrease was primarily due to decreases in professional fees for a total of approximately $0.4 million primarily related to legal and patent expenses and in the Company's D&O insurance premium of approximately $0.9 million as compared to the prior year.

Net Loss

Net loss was approximately $7.2 million, or ($9.08) per share, for the year ended December 31, 2024 as compared with a net loss of approximately $10.8 million, or $46.76 per share, for the year ended December 31, 2023. The decrease in net loss was primarily due to the changes in research and development expenses, as described above.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company advancing its proprietary INTASYL siRNA gene silencing technology to eliminate cancer. INTASYL can target and silence virtually any gene with high degree of specificity across a wide range of cell types and tissues. INTASYL is designed to enhance the ability of immune cells to more effectively kill tumor cells. INTASYL has also demonstrated enhancement to adoptive cell therapy. Notably, INTASYL is a self-delivering RNAi technology focused on immuno-oncology therapeutics without the need for formulation enhancements or manipulations to reach its target.

Phio's lead clinical program, PH-762, is an INTASYL compound that silences PD-1. PH-762 is a potential non-surgical treatment for skin cancers. The on-going Phase 1b trial (NCT# 06014086) received FDA clearance for an Investigational New Drug Application to evaluate PH-762 in the treatment of cutaneous SCC, melanoma and Merkel cell carcinoma in second quarter of 2023.

For additional information, visit the Company's website, www.phiopharma.com.

LMFAO🤣

Me and you know how to make coin, comes easy for us PHIO

HOLY SMACK A RONNIES THE SANFRISCO TREAT PHIO GGGGGGGGGGOOO PHIO

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
Newsfile Corp.
Newsfile Corp
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research Session

Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced that a podium presentation addressing its lead product candidate, PH-762, was given in the Academy's Late-Breaking Research session. The Late-Breaking Research session includes oral presentations of the top-scoring abstracts that address common and complex dermatological conditions.

Mary Spellman, MD, FAAD, presented "PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: Interim Results from an Ongoing Study of INTASYL PH-762" which provided details on the design and progress of Phio's ongoing open-label Phase 1b clinical study (NCT 06014086), to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. Stages 1 and 2 cSCC represent 77% of all new cSCC annually.

Recent data showed that, of the four patients who have completed treatment in the second dose cohort, two patients with cutaneous squamous cell carcinoma achieved a complete response (100% pathological cure) while a third patient with squamous cell carcinoma achieved a partial response (90% pathological cure). The fourth patient in this cohort exhibited stable disease, having not progressed.

The study recently fulfilled the required enrollment for safety in its third dose cohort. Initiation of screening of the fourth dose cohort is planned for early April.

"We are excited to share our progress in this trial with the dermatology community," said Mary Spellman M.D., Phio's acting Chief Medical Officer. "We believe that this immuno-oncology therapy may offer patients meaningful clinical benefit, while minimizing surgical interventions."

WHATS THE RANGE? 40 CENTS? PHIO

Cool on it PHIO

Spuds! Absolutely! Nobody pays much attention to this when its going down but they chase it every time it pops. This is a great one short-term and long🤭

I always like your analytics. Just wait, many will come back strong!😁

YA BIG TIME , RUNNING AROUND NAKED IN THE SNOW , WANT A PICTURE? PHIO

20/30 cents coming PHIO MEOW

phio is the bomb

This is another med sector of over 450 issues
https://www.barchart.com/stocks/quotes/CRSP/competitors?quoteSectors=-283G&viewName=main&orderBy=weightedAlpha&orderDir=desc
The burning question going forward is have a lot of stocks reached absolute bottom?

The broader med sectors have been in a bear market for months
This link to a Barchart webpage has a sector chart for 147:issues, including PHIO
https://www.barchart.com/stocks/quotes/PSTV/competitors?quoteSectors=-MEDR&viewName=main&orderBy=weightedAlpha&orderDir=desc
Provides ample evidence

Way oversold! All it will take is one fairly meaty PR and BANG ZOOM!😷

PHIO under $2

I think PHIO is due for a pop! She has a minimal public float!😍😇

Nice PHIO

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
Newsfile Corp.
Newsfile Corp
Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it has fulfilled the required enrollment for safety in its third dose cohort in its Phase 1b dose escalating clinical study for their lead compound PH-762. The company plans to initiate screening of the fourth dose cohort in early April.

Phio's Phase 1b study (NCT 06014086) is a multi-center, dose-escalating clinical trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This study assesses the tumor response and determines the recommended dose for further study of PH-762.

"We are excited with the rapid completion of enrollment of the third safety cohort," said Robert Bitterman, CEO of Phio Pharmaceuticals. "We look forward to rapidly advancing the study to bring an innovative, alternative treatment option to patients with skin carcinomas."

funny anecdote
this one gave ALNY the schvitz in 2010 because of the IP around RNAi conjugation.
Needless to say thats not the case anymore.
Just goes to show they know exxactly what they are doing with this scam.

OT: I know you are bro🤑 and you need to keep a close tab on RNAZ she is dropping like a rock today. Anything under $ 5.00 is child's play!

ya I'm in just kidding around we are solid , got a boat load of money

Do you want😍 to join me?😋😇😁

1.65 lol u clown sell dip douche

$1.44 new 52-week low. Bought $1.47 on my double down. 😇

Currently, $1.57 nearing its 52-week low of $1.53. Should she drop under $1.50 I'm doubling down.😷

Grabbed $1.79♥️

Very nice indeed! I am still holding that other half from the last time it ran. This Company I like long term as well🤩

$2.20 now ..Picked up $1.90s yesterday and flipped out at $2.60s this morning. Going to grab some more on the new dump for next flip $1.90- 2.20 should be good buying zone today 

Let it get sloppy like last time. 🤣

S-1 Does the forecast call for pain...

Pros: If PHIO demonstrates strong progress in its clinical trials, communicates a clear and effective use of proceeds, and generates positive clinical and financial milestones, the additional 5.9 million shares is a reasonable trade-off for long-term growth.

Cons: If there’s limited progress (no reason to believe there will be with the recent news) delays, or ambiguity about the company’s ability to monetize its pipeline, the market may view the dilution as detrimental, which will be bad, very, very bad indeed.

When will the warrants expire??

Series E Warrants: Exercisable until December 2029 @ $2.51
Series F Warrants: Exercisable until December 2029 @ 2.00
Series G, H, and I Warrants: Exercisable until January 2027 $3.00
Warrants must be exercised voluntarily, and holders typically do so when the market price exceeds the warrant exercise price.

This may get sloppy, so hold on.

PHIO: We are all LONG-GONE with our PROFITS, Dude!!! (Thank you, PHIO company!!!!)

lol told you new offering 

PHIO: See ME, below, workin' on that $10.00, right now!!!

"PLEASE, Oh Lord, give me $10.00 even on PHIO today, & I'll donate 50% of my profits to THE STARVATION ARMY, and SAINT JUDE'S CHILDREN'S REFORMATORY!!"